Advertisement
The new Pharmacor report entitled Rheumatoid Arthritis finds that thenovel TNF-alpha inhibitor golimumab will be one of the most commerciallysuccessful emerging agents for rheumatoid arthritis, due to its more-convenient intravenous and subcutaneous dosing formulations, compared with theformulations of other current and emerging TNF-alpha inhibitors.Additionally, due to its novel mechanism of action, the interleukin-6inhibitor Actemra will successfully compete with Bristol-Myers Squibb'sOrencia and Biogen Idec/Genentech/Chugai/Zenyaku Kogyo's Rituxan / Roche'sMabThera in the treatment of rheumatoid arthritis patients who respondinadequately to TNF-alpha inhibitors.
Advertisement
The report also finds that Amgen/Wyeth/Takeda's Enbrel and Abbott/Eisai'sHumira -- both currently marketed TNF-alpha inhibitors -- will continue todominate the rheumatoid arthritis market. Driven by their continued uptake asfirst-line treatments among biological agents, sales of Enbrel and Humira forrheumatoid arthritis will be close to $4 billion for each drug by 2017.
"Most of the sales growth over the next 10 years will occur through 2012,driven by continued uptake of currently marketed drugs and the launch ofseveral novel biological agents," said Dancella Fernandes, Ph.D., analyst atDecision Resources. "From 2012 to 2017, annual market growth will slow due tofewer new product launches, restrictions imposed by third-party payers thatwill prevent expansion of biological therapy into earlier lines of treatment,biogeneric erosion and smaller increases in the rates of diagnosis and drugtreatment."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in marketresearch publications, advisory services, and consulting designed to helpclients shape strategy, allocate resources, and master their chosen markets.All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders. For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 [email protected]
SOURCE Decision Resources
